Physician
Oncology
Dr. Victor G. Vogel, MD
|
|
Give Review
Victor Vogel works in the field of Oncology. He graduated from Temple University School of Medicine. He received awards:"CMS Meaningful Use Stage 1 Certification". Victor Vogel is a published doctor. He published 61 publications, including: 'Use of pharmacologic interventions for breast cancer risk reduction: american society of clinical oncology clinical practice guideline.' He accepts Medicare.
Publications
- Use of pharmacologic interventions for breast Cancer risk reduction: american society of clinical oncology clinical practice guideline.
- Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention.
- Erythrocyte omega-6 and omega-3 Fatty acids and mammographic Breast density.
- Urinary estrogen metabolites and breast cancer: a combined Analysis of individual level data.
- Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer.
- Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast Cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
- Gynecologic conditions in participants in the NSABP breast Cancer prevention study of tamoxifen and raloxifene (STAR).
- Benefit/Risk assessment for breast Cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
- A method to estimate off-schedule observations in a longitudinal study.
- Menstrual history and quality-of-life outcomes in women with node-positive breast Cancer treated with adjuvant therapy on the NSABP B-30 trial.
- Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention.
- Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast Cancer.
- Tipping the balance for the primary prevention of breast Cancer.
- Longer therapy, iatrogenic amenorrhea, and survival in early breast Cancer.
- Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
- Altering the propensity for density: the benefits and risks of selective estrogen receptor modulators.
- Longitudinal association of anthropometry with mammographic Breast density in the Study of Women's Health Across the Nation.
- Incidence of invasive breast Cancer in postmenopausal women after discontinuation of long-term raloxifene administration.
- Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast Cancer.
- Managing the risk of breast Cancer in postmenopausal women: introduction.
- Risedronate prevents bone loss in breast Cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
- What do perceived cognitive problems reflect?
- Preventing breast Cancer in high-risk women, 2008.
- Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat Analysis of the National Surgical Adjuvant Breast And Bowe...
- Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women.
- Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
- Breast Cancer prevention.
- Breast Cancer risk management.
- Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast Cancer.
- Ontology, oncology, and preventive economies: developing drugs for Cancer prevention.
- Breast Cancer risk assessment and risk reduction.
- Chemoprevention strategies 2006.
- Prevention of bone loss in survivors of breast Cancer: A randomized, double-blind, placebo-controlled clinical trial.
- Referral to Cancer genetic counseling: are there stages of readiness?
- Identifying and screening patients at risk of second Cancers.
- Breast Cancer-related lymphedema--what are the significant predictors and how they affect the severity of lymphedema?
- Recent results from clinical trials using SERMs to reduce the risk of breast Cancer.
- Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast Cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (...
- Have we found the ultimate risk factor for breast Cancer?
- Endogenous sex hormones, breast Cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
- Can statin therapy reduce the risk of breast Cancer?
- Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant ther...
- Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate Cancer cells is mediated by...
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast Cancer.
- Impact of sentinel lymph node biopsy on lymphedema following breast Cancer treatment.
- Pemetrexed/oxaliplatin for first-line treatment of patients with advanced coloRectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Projec...
- Atypia in the assessment of breast Cancer risk: implications for management.
- Current comprehensive assessment and management of women at increased risk for breast Cancer.
- Recognition and management of hereditary breast Cancer syndromes.
- Management of the high-risk patient.
- Update on breast Cancer prevention.
- Preventing hormone-dependent breast Cancer in high-risk women.
- Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.
- National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of Ductal carcinoma in situ.
- Re: tamoxifen for prevention of breast Cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
- The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast Cancer risk reduction trial.
- Why do we still use hormone replacement therapy? Why don't we use it more?
- Prevention in the balance.
- The Relationship Between Tamoxifen, Estrogen, and Depressive Symptoms.
- Optimal Management of Primary Breast Cancer.
Schools
Temple University
Baltimore City Hosps
Johns Hopkins Hospital
Johns Hopkins University
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Capital Blue Cross
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- Community Blue PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Johns Hopkins University -
Johns Hopkins Bayview Medical Center -
Temple University School of Medicine
Drug Facts
| NPI NUMBER | 1700852233 | |
| NPPES Provider LastName | VOGEL | |
| NPPES Provider FirstName | VICTOR | |
| NPPES Provider ZIPCode | 152133108 | |
| NPPES Provider State | PA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 697.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700852233 |
| Last Name Of The Provider | VOGEL |
| First Name Of The Provider | VICTOR |
| View All |
Similar Doctors
|
|
Dr. James R. Bosscher, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Neil M. Ellison, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Albert M. Bernath Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samir A. Kheiri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles F. White, MD
This Doctor is OpenDoctor Recommended.
|